Tarsus Pharmaceuticals Inc (TARS)

Finanzdaten der Tarsus Pharmaceuticals Inc-Aktie (TARS)

Gewinn- und Verlustrechnung

Vierteljährlich

*Alle Zahlen in Millionen

Enddatum des Zeitraums	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31
Periodenlänge	3 Monate	3 Monate	3 Monate	3 Monate	3 Monate
Revenues	111.18% 27.61	13.08	1.871	-	2.50
Operating Expenses	13.51% 65.30	57.53	42.81	32.82	27.45
Interest Income/Expense	0.61% 0.983	0.989	0.858	0.815	0.684
Benefits Costs and Expenses	29.92% 65.30	50.26	42.81	32.82	29.95
Costs And Expenses	29.92% 65.30	50.26	42.81	32.82	27.45
Operating Income/Loss	15.22% -37.68	-44.45	-40.94	-32.82	-24.95
Nonoperating Income/Loss	23.35% 1.953	2.548	1.787	1.397	1.533
Income/Loss From Continuing Operations Before Tax	1.34% -37.68	-37.19	-40.94	-31.42	-23.42
Income/Loss From Continuing Operations After Tax	14.73% -35.73	-41.90	-39.15	-31.42	-23.42
Net Income/Loss	14.73% -35.73	-41.90	-39.15	-31.42	-23.42
Preferred Stock Dividends And Other Adjustments	-	-	-	-	-
Attributable To Noncontrolling Interest	-	-	-	-	-
Basic Average Shares	2,579% 35.30	1.3178	30.62	26.82	26.74
Diluted Average Shares	2,579% 35.30	1.3178	30.62	26.82	26.74
Basic Earnings Per Share	20.47% -1.01	-1.27	-1.28	-1.17	-0.88
Diluted Earnings Per Share	20.47% -1.01	-1.27	-1.28	-1.17	-0.88
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic	-	-	-	-	-